Frequently Asked Questions (FAQs)

How long are patients enrolled in the Rituxan Immunology and ACTEMRA Co-pay Card Program?

Patients may receive up to $15,000 in assistance per 12-month period. Program benefits reset every 12 months from date of enrollment as long as the patient remains eligible.

If patients switch from ACTEMRA intravenous (IV) to ACTEMRA subcutaneous (SC) (or vice versa), do they have to reapply to the program?

ACTEMRA Intravenous (IV) and ACTEMRA for self-injection are FDA-approved for use in moderate to severe patients that have had an inadequate response to a DMARD and patients with polyarticular juvenile idiopathic arthritis (PJIA). If you are this type of patient, and switching from ACTEMRA IV to ACTEMRA for self-injection, you do not need to reapply for the program. Once you qualify and are enrolled in the program, you are eligible to receive $15,000 per 12-month period, subject to submission of documents required for funding of the card with co-pay assistance payments. Note that ACTEMRA for self-injection is not approved for use in patients with systemic juvenile idiopathic arthritis (SJIA) and ACTEMRA IV is not approved for use in giant cell arteritis (GCA) patients. The ACTEMRA Co-Pay Card Program provides drug co-pay assistance for out-of-pocket costs of ACTEMRA only when ACTEMRA IV or ACTEMRA self-injection is prescribed for an approved use.

If patients switch from one Genentech medicine to the other, do they have to reapply to the program?

Yes. Each card can be used for either Rituxan or ACTEMRA only. Patients who switch to a different Genentech medicine can reapply to receive assistance for the new medicine.

What if a patient forgot to apply and has already received treatment?

Patients must be enrolled in the program before their treatment. However, under certain circumstances, an exception may be possible. Please call (855) RA-COPAY (855-722-6729) for more information.

How many treatments does the program cover?

There is no limit to the number of Rituxan or ACTEMRA treatments the program covers. Treatments will be covered until the $15,000 limit is reached.

Does the program help with administration costs or co-pays for office visits?

No. The program only helps with the co-pay for Rituxan or ACTEMRA. It does not help with other costs, like IV infusions or office visits.

Can the program be used by Rituxan patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or pemphigus vulgaris (PV)?

Yes. The program is available to all eligible commercially insured patients taking Rituxan for an approved indication.

Can the program be used by ACTEMRA patients with giant cell arteritis (GCA)?

Yes. The program is available to all eligible commercially insured ACTEMRA for self-injection patients with giant cell arteritis (GCA).

Can the program be used by ACTEMRA patients with systemic juvenile idiopathic arthritis (SJIA) or polyarticular juvenile idiopathic arthritis (PJIA) who are under 18?

Yes. The program is available to all eligible commercially insured patients taking ACTEMRA for an approved indication. The patient's guardian or legally authorized person who is 18 years or older would need to apply for the co-pay assistance on behalf of the patient under 18.

What if the patient forgets to bring the card to the appointment?

Patients can call (855) RA-COPAY (855-722-6729) from their doctor's office. The help desk hours are from 6 a.m.–5 p.m. PT, Monday through Friday, except major holidays. We will give the account number over the phone.

May patients use the Rituxan Immunology and ACTEMRA Co-pay Card Program at an outside infusion center?

Yes. Patients may use the program anywhere they get their Rituxan or ACTEMRA treatments as long as their infusion center accepts the card.

Will patients be asked for other information once they are enrolled in the program?

Yes. Patients will be asked to send copies of their detailed Explanation of Benefits (EOB) statements after each infusion or injection. This information is required to fund the card.

Can patients use the Genentech® Access to Care Foundation (GATCF) and the Rituxan Immunology and ACTEMRA Co-pay Card Program at the same time?

No. Patients who are getting help with their drug co-pay for Rituxan or ACTEMRA from GATCF or other patient assistance programs cannot use the Rituxan Immunology and ACTEMRA Co-pay Card Program. Call (866) 681-3261 or visit Genentech-Access.com/Rheumatology to learn more about GATCF and other patient assistance programs from Genentech Rheumatology Access Solutions.

Can patients or doctors get a refund from a health plan for the co-pay paid by the card?

No. Patients and doctors cannot receive reimbursement from a health plan or anyone else for the amount paid by the card.

How can my practice find out how much money is left on the card?

Practices can log in to the Tool Center to see a list of all their patients' card balances and expiration dates or call (855) RA-COPAY (855-722-6729) from 6 a.m.–5 p.m. PT, Monday through Friday, except major holidays.

Where do I enter my practice's bank account information when requesting the Rituxan Immunology and ACTEMRA Co-pay Card Program Electronic Funds Transfer (EFT) option for co-pay payment?

After logging in to the Tool Center, click on the Physician Profile tab and fill in the "Optional Bank Account Information for EFT" part of the page.



If you have any additional questions, please call (855) RA-COPAY (855-722-6729) from 6 a.m.–5 p.m. PT, Monday through Friday, except major holidays.

Indication and Important Safety Information

 

  • Rituxan® (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapies
  • Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)
  • Rituxan® (rituximab), is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris

Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions.

Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan.

Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation.

Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan.

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

  • Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function
  • Infections: Withhold Rituxan and institute appropriate anti-infective therapy. Rituxan is not recommended for use in patients with severe, active infections
  • Cardiovascular adverse reactions: Discontinue infusions in case of serious or life-threatening events
  • Renal toxicity: Discontinue in patients with rising serum creatinine or oliguria
  • Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms
  • Immunizations: Live virus vaccinations prior to or during Rituxan treatment are not recommended
  • Embryo-Fetal toxicity: Can cause neonatal harm. Advise of potential risk to neonates and use of effective contraception
  • Patients with RA should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
  • The use of Rituxan in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended
  • Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA, MPA, or PV patients exhibiting peripheral B-cell depletion following treatment with Rituxan
  • The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA

Rheumatoid Arthritis (RA)
Most common adverse reactions (≥10%) in clinical trials: upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis. Other important adverse reactions include infusion reactions, serious infections, and cardiovascular events.

Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
Most common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions.

Pemphigus Vulgaris (PV)
Most common adverse reactions (≥15%) in the clinical trial were infusion reactions and depression. Other important adverse reactions include infections.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional Important Safety Information, please see the Rituxan full Prescribing Information, including BOXED WARNINGS.

ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

ACTEMRA is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

RISK OF SERIOUS INFECTIONS:

Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.

Reported infections include:

  • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
  • Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
  • Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.

Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Use ACTEMRA with caution in patients who may be at risk for GI perforations.

Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests.

Hypersensitivity reactions, including anaphylaxis and death, have occurred.

  • If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently.

Avoid use of live vaccines concurrently with ACTEMRA, as clinical safety has not been established.

Other potential risks of ACTEMRA include demyelinating disorders and malignancies.
Treatment with ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.

Common adverse reactions included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, diarrhea and injection-site reactions (SC only).

Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea.

In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see accompanying full Prescribing Information, including BOXED WARNING, for additional important safety information.